UK's Syn­thace rais­es $35M in Se­ries C; On­col­o­gy and in­flam­ma­to­ry dis­ease biotech De­ka hauls in $20M Se­ries A

UK-based AI-as­sist­ed R&D biotech Syn­thace just wrapped up a Se­ries C round, bring­ing in $35 mil­lion.

Per a com­pa­ny state­ment this morn­ing, the in­vest­ment will fu­el com­mer­cial and go-to-mar­ket (GTM) growth as Syn­thace con­tin­ues to ex­pand across the At­lantic in­to the US. This in­cludes plans to ex­pand its lead­er­ship team by bring­ing in new VPs of mar­ket­ing and sales to join US-based Guy Levy-Yurista, Syn­thace’s CEO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.